GLP and GCP [Bioanalytics]

posted by Ohlbe – France, 2009-05-18 12:22 (6252 d 06:54 ago) – Posting: # 3694
Views: 7,178

Dear Helmut,

Basically, what NewInPK and you are suggesting is to do ISR, but with a different method :-)

Oh, another possible source of problems, not studied during validation, but which would be found this way: the influence of some excipients, such as Tween 80 or PEG 400. Not found in BE studies, but common in pre-clinical, and possibly in early clinical trials. Can cause matrix effects. Several publications showing these substances to be problematic after IV administration ; possibly also after oral administration.

❝ I know at least one. :-D


The French inspector I know you have met is a GCP inspector, not GLP. But I've heard he works closely with his GLP colleagues.

Regards
Ohlbe

Complete thread:

UA Flag
Activity
 Admin contact
23,656 posts in 4,994 threads, 1,571 registered users;
337 visitors (0 registered, 337 guests [including 21 identified bots]).
Forum time: 19:17 CEST (Europe/Vienna)

It requires a very unusual mind
to undertake the analysis of the obvious.    Alfred North Whitehead

The Bioequivalence and Bioavailability Forum is hosted by
BEBAC Ing. Helmut Schütz
HTML5